摘要
目的:考察P-糖蛋白抑制剂HZ08对K562/ADM接种裸鼠体内肿瘤多药耐药的逆转作用及HZ08对大鼠肝P450酶亚型的影响。方法:K562/ADM接种的裸鼠尾静脉注射HZ08和阿霉素4周,与对照组和阳性药组比较瘤重;HZ08与CYP450亚型特异性底物在大鼠肝微粒体中温孵,与对照组比较测定HZ08对于CYP450亚型的影响。结果:HZ08可显著减小裸鼠体内的瘤重,并对大鼠肝微粒体CYP3A4有较弱的抑制作用,对其他P450酶亚型无显著抑制作用。结论:HZ08在裸鼠体内具有较好的逆转P-糖蛋白介导的肿瘤多药耐药的作用,并且在体外实验中对P450酶具有较小的影响。
Aim: To evaluate the effects of HZ08, a novel P-glycoprotein inhibitor, on reversing tumor resistance of K562/ADM to adriamycin in nude mice and on the activities of cytochromes P-450 (CYP) isoforms. Methods: Nude mice bearing K562/ADM were injected at different doses of HZ08 with adriamycin for 4 weeks. The tumor weights of HZ08 treatment groups were determined and compared to those of the control and positive groups. In addition, the effects of HZ08 were examined on CYP isoforms-mediated metabolism of specific substrates by CYP isoforms in rat liver microsomes in the presence or absence of HZ08. Results: The tumor weights of HZ08 treat- ment groups were significantly decreased and HZ08 was a relatively potent inhibitor of CYP3A4, with no significant effects on other isoforms tested. Conclusion: HZ08 has potent effects on reversing P-glycoprotein mediated tumor multidrug resistance in vivo with little influence on cytochrome P-450 activities of rat liver.
出处
《中国药科大学学报》
CAS
CSCD
北大核心
2008年第5期447-452,共6页
Journal of China Pharmaceutical University
基金
supported by the National High Technology Research and Development Program of China(No.2002AA233071)